Beiersdorf prelim sales, earnings down in 2009
This article was originally published in The Rose Sheet
Hamburg, Germany-based firm records preliminary sales of €5.7 bil. ($8.3 bil.) for fiscal 2009, down 3.6 percent from the year prior. Sales in its consumer business segment, which includes Eucerin and NIVEA brands, were down 2.2 percent to €5.01 bil. ($7.2 bil.), though organic sales of the unit increased 1.2 percent. Although sales in Western Europe declined, revenues in the U.S., China and Latin America rose. Profit after taxes fell 33 percent to €379 mil. ($544.8 mil.). Beiersdorf's final results for the fiscal year will be released at an analyst meeting March 4
You may also be interested in...
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.